ArticleDeutsches Arzteblatt international2020
Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease.
Article in Deutsches Arzteblatt international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Genetically Determined Loss-of-Function of the Organic Cation Transporter OCT1 Is Associated with Lower Liver Fat Content in Humans.International journal of molecular sciences · 2026Article
- Metabolic dysfunction-associated steatohepatitis in the real world: clinical burden, disease progression, and risk stratification with non-invasive tests.BMC gastroenterology · 2026Article
- Association between metabolic dysfunction-associated steatotic liver disease and breast cancer risk in Korean women: a nationwide population-based cohort study.Breast cancer research : BCR · 2026Article
- Serum protein risk stratification score for diagnostic evaluation of metabolic dysfunction-associated steatohepatitis.Hepatology communications · 2024Article
- What Is the Link between Attention-Deficit/Hyperactivity Disorder (ADHD) and Dyslipidemia in Adults? A German Retrospective Cohort Study.Journal of clinical medicine · 2024Article
- Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD).European journal of medical research · 2023Article
- Comorbidities and Malignancy among NAFLD Patients Compared to the General Population, A Nation-Based Study.Biomedicines · 2023Article
- Antibiotic therapy is associated with an increased incidence of cancer.Journal of cancer research and clinical oncology · 2023Article
- Fatty Liver and Risk of Head and Neck Cancer in Type 2 Diabetes Mellitus: A Nationwide Cohort Study.Cancers · 2023Article
- Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.Clinical and molecular hepatology · 2023Review
- The Landscape of Outpatient Palliative Care in Germany: Results from a Retrospective Analysis of 14,792 Patients.International journal of environmental research and public health · 2022Article
- Low blood levels of high-density lipoprotein (HDL) cholesterol are positively associated with cancer.Journal of cancer research and clinical oncology · 2022Article
- Red Pepper Seeds Inhibit Hepatic Lipid Accumulation by Inducing Autophagy via AMPK Activation.Nutrients · 2022Article
- Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?Current oncology (Toronto, Ont.) · 2022Review
- Comorbidities Are Associated with Fibrosis in NAFLD Subjects: A Nationwide Study (NASH-CO Study).Digestive diseases and sciences · 2022Article
- Hepatic Steatosis and Fibrosis in Chronic Inflammatory Bowel Disease.Journal of clinical medicine · 2022Article
- Article
- Incidence of Cancer in Patients with Irritable Bowl Syndrome.Journal of clinical medicine · 2021Article
- The Role of Physical Activity in Nonalcoholic and Metabolic Dysfunction Associated Fatty Liver Disease.Biomedicines · 2021Review
- Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany.United European gastroenterology journal · 2021Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence of cancer is increasing worldwide. The role of comorbidities in this development is debated. The aim of this study was to investigate the significance of non-alcoholic fatty liver disease (NAFLD) for the incidence of cancer of various kinds in Germany.
methodsBetween 2000 and 2015, data on 31 587 patients with established NAFLD were collected for analysis. A control group (n = 31 587) assembled for comparison was matched for sex, age, treating physician, and Charlson Comorbidity Index (CCI).
resultsBy 10 years after the index date, 15.3% of patients with NAFLD and 13.4% of patients in the control group had been diagnosed with cancer (p <0.001). Patients with NAFLD exhibited significantly higher rates of male genital cancers (HR 1.26; 95% confidence interval [1.06; 1.5]; p = 0.008), skin cancer (HR 1.22 [1.07; 1.38]; p = 0.002) and breast cancer (HR 1.2 [1.01; 1.43]; p = 0.036). In this analysis, the rate of hepatocellular carcinoma did not differ between patients with NAFLD and patients without NAFLD (0.19% vs. 0.12%; p = 0.204).
conclusionNAFLD slightly increases the risk of breast cancer in women, genital cancer in men, and skin cancer irrespective of sex. Thus, NAFLD can be considered a marker of increased cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.